PT109
Based on 1 Customer Validation
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.20%
- No. CAS: 2059104-90-2
- Fòrmula: C23H31N3OS2
- Peso molecular:429.64
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Lactylation Compound Library
HY-L249
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
|
JNK1 0.143 μM (IC50) |
JNK2 0.831 μM (IC50) |
JNK3 0.285 μM (IC50) |
SGK1 1.34 μM (IC50) |
SGK2 5.6 μM (IC50) |
SGK3 26.4 μM (IC50) |
ROCK2 34 μM (IC50) |
MMP-9 |
MMP-2 |
COX-2 |
iNOS |
PKM1 |
PT109 (10 μM; 24 h) significantly reduces the proportion of Ki67-positive (proliferative) human glioblastoma T98G and U251 cells[1].
PT109 (10-20 μM; 24 h, 72 h) reduces the proteolytic activity and protein expression of MMP-2 and MMP-9 in a dose-dependent manner in T98G and U251 human glioblastoma cells, downregulates the expression of stem cell, astrocyte and neuron markers, while upregulating the expression of oligodendrocyte markers (MBP, MOG), induces morphological changes in T98G, U251 and U87 human glioblastoma cells[1].
PT109 (10-20 μM; 72 h, 1-7 days) reduces the protein levels of PTBP1 and PKM2 in a dose- and time-dependent manner, while increasing the PKM1 level and the PKM1/PKM2 ratio, in human glioblastoma U251 cells, with the most significant effect observed at 20 μM for 7 days[1].
PT109 (10 μM; 3 d) promotes the differentiation of C17.2 mouse neural stem cells into cholinergic neurons, upregulates the expression of neurogenesis markers and cholinergic markers, and does not induce astrocyte differentiation[2].
PT109 (0.3-3 μM; 3 d) promotes synaptogenesis in primary rat hippocampal neurons and cortical neurons by upregulating the expression of the synaptogenesis marker Synapsin-1[2].
PT109 (100 μg/mL; 10 h) exhibits favorable blood-brain barrier permeability in the in vitro PAMPA-BBB assay, indicating its potential for central nervous system exposure[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U251 human glioblastoma cell line
-
Concentration:10, 20 μM (dose-response; 72 h); 20 μM (time-course; 1, 3, 7 days)
-
Incubation Time:72 h; 1, 3, 7 days
-
Result:Increased PKM1 protein levels and the PKM1/PKM2 ratio, and decreased PTBP1 and PKM2 protein levels, in a dose-dependent manner over 72 h. Decreased PTBP1 and PKM2 levels in a time-dependent manner, and increased PKM1 levels and the PKM1/PKM2 ratio in a time-dependent manner, over 7 days of treatment with 20 μM, with the most significant effects observed at 7 days (P<0.001 for PTBP1 reduction).
-
Cell Line:C17.2 murine neural stem cells
-
Concentration:10 μM
-
Incubation Time:3 days
-
Result:Increased the expression of Tuj-1 and MAP2 compared to vehicle control. Remarkably increased ChAT expression but showed no significant effect on GFAP expression relative to control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:APP/PS1 mice with Alzheimer's disease (male, 3 months old at study start, B6C3 background, Alzheimer's disease transgenic model)[2]
-
Dosage:30 mg/kg; 100 mg/kg
-
Administration:oral; daily via diet; 3 or 6 months
-
Result:Reduced Morris water maze escape latencies on day 5 (100 mg/kg, 6 months treatment).\n
Increased step-through test escape latency and reduced error frequency (100 mg/kg, 6 months treatment).\n
Significantly reduced number of activated microglia (Iba1-positive cells) and activated astrocytes (GFAP-positive cells) in brain cortex and hippocampus (30 mg/kg or 100 mg/kg, 3 or 6 months treatment).\nSignificantly reduced hippocampal levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6 (30 mg/kg or 100 mg/kg, 6 months treatment).\n
Significantly reduced hippocampal levels of phosphorylated JNK (p-JNK) (30 mg/kg or 100 mg/kg, 6 months treatment).\n
Significantly reduced hippocampal and cortical levels of phosphorylated Tau (p-Tau, S396) (30 mg/kg or 100 mg/kg, 6 months treatment).
Chemical Information
-
No. CAS 2059104-90-2
-
Appearance Solid
-
Peso molecular 429.64
-
Fòrmula C23H31N3OS2
-
Color Light yellow to yellow
-
SMILES
O=C(CCCCC1SSCC1)NC2CCC(CC2)NC3=CC=CC4=C3C=CN=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 100 mg/mL (232.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Yang Y, et al. PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway. Eur J Pharmacol. 2022;920:174837. [Content Brief]
[2]. Chen Q, et al. Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo. Eur J Pharmacol. 2020;883:173361. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3275 mL | 11.6376 mL | 23.2753 mL | 58.1882 mL |
| 5 mM | 0.4655 mL | 2.3275 mL | 4.6551 mL | 11.6376 mL | |
| 10 mM | 0.2328 mL | 1.1638 mL | 2.3275 mL | 5.8188 mL | |
| 15 mM | 0.1552 mL | 0.7758 mL | 1.5517 mL | 3.8792 mL | |
| 20 mM | 0.1164 mL | 0.5819 mL | 1.1638 mL | 2.9094 mL | |
| 25 mM | 0.0931 mL | 0.4655 mL | 0.9310 mL | 2.3275 mL | |
| 30 mM | 0.0776 mL | 0.3879 mL | 0.7758 mL | 1.9396 mL | |
| 40 mM | 0.0582 mL | 0.2909 mL | 0.5819 mL | 1.4547 mL | |
| 50 mM | 0.0466 mL | 0.2328 mL | 0.4655 mL | 1.1638 mL | |
| 60 mM | 0.0388 mL | 0.1940 mL | 0.3879 mL | 0.9698 mL | |
| 80 mM | 0.0291 mL | 0.1455 mL | 0.2909 mL | 0.7274 mL | |
| 100 mM | 0.0233 mL | 0.1164 mL | 0.2328 mL | 0.5819 mL |
PT109 Related Classifications
HY-167832 Related Classifications
Powered by Bioz